Javascript must be enabled to continue!
Abstract A37: The BRAF pseudogene is a proto-oncogenic competitive endogenous RNA.
View through CrossRef
Abstract
Noncoding RNAs have long been viewed as non-functional genomic relicts of evolution, but recetn findings have implicated their importance in physiology and disease. Recently, in vitro experiments demonstrated that the pseudogenes of PTEN and KRAS operate as natural miRNA decoys (competitive endogenous RNAs or ceRNAs) that regulate the expression of their parental genes. However, in vivo evidence for a causal role of pseudogenes in cancer development is lacking. To investigate whether the BRAF pseudogene (BRAFps) possesses oncogenic properties we generated transgenic mice carrying a Tet-inducible BRAF pseudogene allele. Global BRAFps overexpression resulted in the development of aggressive B-cell lymphoma after 6-12 months. These tumors were characterized by a profound expansion of B-lymphocytes in the spleen, as well as splenomegaly, lymphadenopathy and infiltration of the kidneys, lungs, and liver by neoplastic cells. The BRAFps-induced lymphoma was polyclonal, transplantable, dependent on continuous BRAFps expression, and cooperated with heterozygous loss of PTEN to accelerate disease onset. Mechanistically, we propose that BRAFps functions as a ceRNA that sequesters miRNAs from BRAF and possibly other targets. Indeed, overexpression of BRAFps results in elevated levels of BRAF in a Dicer-dependent manner. This, in turn, increased BRAF-dependent MAPK signaling and proliferation. To further validate the ceRNA activity of BRAFps, we engineered mice to express only the 3'UTR or CDS of BRAFps as each portion of the pseudogene may individually engage in miRNA-mediated crosstalk with BRAF. Notably, both BRAFps-CDS and BRAFps-3'UTR increased spleen and lymph node weights 6 months after induction. Interestingly, BRAFps-3'UTR elicited a lymphoma phenotype similar to full length BRAFps, while mice expressing BRAFps-CDS developed a more indolent form of this phenotype, suggesting that lymphomagenesis is primarily mediated by the BRAFps 3'UTR. BRAFps transcript was undetectable in primary human B-cells, but was aberrantly expressed in primary human DLBCL and human DLBCL cell lines. Expression of BRAF and BRAFps was positively correlated in human primary DLBCL and human DLBCL cell lines. In addition, gains or amplifications of the genomic locus containing BRAFps were found in various human cancer types. Overexpression of BRAFps in human lymphoma cells elevated BRAF levels, MAPK activation, proliferation and growth in xenografts. Our results demonstrate for the first time the oncogenic potential of a pseudogene in an engineered mouse model and indicate that ceRNA- mediated regulation is an important regulatory mechanism of gene expression in vivo.
Citation Format: Florian A. Karreth, Markus Reschke, Chapuy Bjoern, Margaret Shipp, Roberto Chiarle, Pier Paolo Pandolfi. The BRAF pseudogene is a proto-oncogenic competitive endogenous RNA. [abstract]. In: Proceedings of the AACR Special Conference on Hematologic Malignancies: Translating Discoveries to Novel Therapies; Sep 20-23, 2014; Philadelphia, PA. Philadelphia (PA): AACR; Clin Cancer Res 2015;21(17 Suppl):Abstract nr A37.
American Association for Cancer Research (AACR)
Title: Abstract A37: The BRAF pseudogene is a proto-oncogenic competitive endogenous RNA.
Description:
Abstract
Noncoding RNAs have long been viewed as non-functional genomic relicts of evolution, but recetn findings have implicated their importance in physiology and disease.
Recently, in vitro experiments demonstrated that the pseudogenes of PTEN and KRAS operate as natural miRNA decoys (competitive endogenous RNAs or ceRNAs) that regulate the expression of their parental genes.
However, in vivo evidence for a causal role of pseudogenes in cancer development is lacking.
To investigate whether the BRAF pseudogene (BRAFps) possesses oncogenic properties we generated transgenic mice carrying a Tet-inducible BRAF pseudogene allele.
Global BRAFps overexpression resulted in the development of aggressive B-cell lymphoma after 6-12 months.
These tumors were characterized by a profound expansion of B-lymphocytes in the spleen, as well as splenomegaly, lymphadenopathy and infiltration of the kidneys, lungs, and liver by neoplastic cells.
The BRAFps-induced lymphoma was polyclonal, transplantable, dependent on continuous BRAFps expression, and cooperated with heterozygous loss of PTEN to accelerate disease onset.
Mechanistically, we propose that BRAFps functions as a ceRNA that sequesters miRNAs from BRAF and possibly other targets.
Indeed, overexpression of BRAFps results in elevated levels of BRAF in a Dicer-dependent manner.
This, in turn, increased BRAF-dependent MAPK signaling and proliferation.
To further validate the ceRNA activity of BRAFps, we engineered mice to express only the 3'UTR or CDS of BRAFps as each portion of the pseudogene may individually engage in miRNA-mediated crosstalk with BRAF.
Notably, both BRAFps-CDS and BRAFps-3'UTR increased spleen and lymph node weights 6 months after induction.
Interestingly, BRAFps-3'UTR elicited a lymphoma phenotype similar to full length BRAFps, while mice expressing BRAFps-CDS developed a more indolent form of this phenotype, suggesting that lymphomagenesis is primarily mediated by the BRAFps 3'UTR.
BRAFps transcript was undetectable in primary human B-cells, but was aberrantly expressed in primary human DLBCL and human DLBCL cell lines.
Expression of BRAF and BRAFps was positively correlated in human primary DLBCL and human DLBCL cell lines.
In addition, gains or amplifications of the genomic locus containing BRAFps were found in various human cancer types.
Overexpression of BRAFps in human lymphoma cells elevated BRAF levels, MAPK activation, proliferation and growth in xenografts.
Our results demonstrate for the first time the oncogenic potential of a pseudogene in an engineered mouse model and indicate that ceRNA- mediated regulation is an important regulatory mechanism of gene expression in vivo.
Citation Format: Florian A.
Karreth, Markus Reschke, Chapuy Bjoern, Margaret Shipp, Roberto Chiarle, Pier Paolo Pandolfi.
The BRAF pseudogene is a proto-oncogenic competitive endogenous RNA.
[abstract].
In: Proceedings of the AACR Special Conference on Hematologic Malignancies: Translating Discoveries to Novel Therapies; Sep 20-23, 2014; Philadelphia, PA.
Philadelphia (PA): AACR; Clin Cancer Res 2015;21(17 Suppl):Abstract nr A37.
Related Results
Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated
Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated
Abstract
BACKGROUND. Most mutations in melanoma affect one critical amino acid on BRAF gene, resulting in the V600E substitution. Patient management is often based on the u...
Abstract 468: BRAF mutation analysis in cell free tumoral DNA (cfDNA) of melanoma patients: results from the prospective study GEM1304 (Spanish Melanoma Group)
Abstract 468: BRAF mutation analysis in cell free tumoral DNA (cfDNA) of melanoma patients: results from the prospective study GEM1304 (Spanish Melanoma Group)
Abstract
Backgroud: Tumor-derived circulating cell-free DNA (cfDNA) is a dynamic source for determination of tumor mutation status. We have previously demonstrated t...
Unveiling the Domain-Specific and RAS Isoform-Specific Details of BRAF Regulation
Unveiling the Domain-Specific and RAS Isoform-Specific Details of BRAF Regulation
Abstract
BRAF is a key member in the MAPK signaling pathway essential for cell growth, proliferation, and differentiation. Dysregulation or mutation of BRAF is ofte...
Data from Wnt/β-Catenin Pathway Activation Mediates Adaptive Resistance to BRAF Inhibition in Colorectal Cancer
Data from Wnt/β-Catenin Pathway Activation Mediates Adaptive Resistance to BRAF Inhibition in Colorectal Cancer
<div>Abstract<p>One of the most encouraging developments in oncology has been the success of BRAF inhibitors in <i>BRAF</i>-mutant melanoma. However, in con...
Data from Wnt/β-Catenin Pathway Activation Mediates Adaptive Resistance to BRAF Inhibition in Colorectal Cancer
Data from Wnt/β-Catenin Pathway Activation Mediates Adaptive Resistance to BRAF Inhibition in Colorectal Cancer
<div>Abstract<p>One of the most encouraging developments in oncology has been the success of BRAF inhibitors in <i>BRAF</i>-mutant melanoma. However, in con...
Unveiling the Domain-Specific and RAS Isoform-Specific Details of BRAF Regulation
Unveiling the Domain-Specific and RAS Isoform-Specific Details of BRAF Regulation
Abstract
BRAF is a key member in the MAPK signaling pathway essential for cell growth, proliferation, and differentiation. Dysregulation or mutation of BRAF is ofte...
Real world characteristics and outcomes of patients with BRAFV600E-mutant metastatic colorectal cancer in Australia: The COALA project.
Real world characteristics and outcomes of patients with BRAFV600E-mutant metastatic colorectal cancer in Australia: The COALA project.
70
Background:
BRAFV600E-mutant metastatic colorectal cancer (mCRC) represents a unique molecular subset with poor prognosis and less ...
Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated
Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated
Abstract
Most mutations in melanoma affect one critical amino acid on BRAF gene, resulting in the V600E substitution. Patient management is often based on the use of specif...

